Kingswood Wealth Advisors LLC Sells 1,431 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kingswood Wealth Advisors LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 57.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,065 shares of the biopharmaceutical company’s stock after selling 1,431 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $759,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. Icon Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares during the period. State Street Corp raised its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in Regeneron Pharmaceuticals by 40.2% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock valued at $204,598,000 after acquiring an additional 55,828 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.1 %

REGN opened at $687.27 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company’s 50 day simple moving average is $724.48 and its two-hundred day simple moving average is $930.31. The firm has a market capitalization of $75.52 billion, a price-to-earnings ratio of 17.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20.

Analysts Set New Price Targets

A number of research firms have recently weighed in on REGN. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Bank of America reiterated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Barclays reduced their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.